Tag: Eli Lilly and Company
Lilly’s donanemab reduces Alzheimer’s disease progression in Phase 2 trial
ALZ results revealed by Eli Lilly and Company at the recent 15th International Conference on Alzheimer's & Parkinson Diseases 2021 (AD/PD 2021) expand on...
Lilly’s tirzepatide brings down body weight in people with type 2...
Lilly's Tirzepatide led to superior A1C and body weight reductions from baseline in adults with type 2 diabetes.
This was achieved after 40 weeks of...
Lilly’s Bamlanivimab to be used as Covid-19 treatment
Bamlanivimab (LY-CoV555), a neutralising antibody emerged from collaboration between Lilly and Vancouver-based AbCellera, has been given authorisation by Health Canada, under the Interim Order...
